ArticleFrontiers in immunology2026
Study on the effects of estimated dose of radiation to immune cells and CBC parameters on the prognosis of patients with locally advanced non-small cell lung cancer undergoing radiotherapy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Locally advanced non-small-cell lung cancer (LA-NSCLC) is a subtype of lung cancer with substantial heterogeneity in clinical prognosis. Immune injury induced by radiotherapy exposure is a critical factor affecting treatment response and long-term outcomes. This study enrolled patients with LA-NSCLC to investigate the prognostic value of complete blood count (CBC) parameters combined with the estimated dose of radiation to immune cells (EDRIC), aiming to facilitate precision prognostic stratification and tailored treatment strategies in clinical practice. Materials and methods: This study included 329 patients with LA-NSCLC who received radiotherapy (RT) at our institution. Serial CBC measurements were obtained pre-RT, weekly during RT, and 1-month post-RT. EDRIC was calculated based on the model developed by Jin et al. and improved by Ladbury et al. We subsequently evaluated the associations of EDRIC and CBC parameters with overall survival (OS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS). Results: Univariate and multivariate analyses demonstrated that EDRIC, together with week 3 platelet-to-lymphocyte ratio (PLR), was significantly associated with OS, LRFS, DMFS, and PFS ( Conclusions: EDRIC is an independent prognostic biomarker for OS, LRFS, PFS and DMFS in LA-NSCLC patients undergoing definitive thoracic (chemo)radiotherapy. Week 3 PLR also independently predicts all four survival endpoints. Compared with the EDRIC-only model, the integrated model incorporating pretreatment EDRIC, clinical variables, and on-treatment inflammatory markers (NLR and PLR) yields more accurate and comprehensive prognostic stratification for patients with LA-NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.